MARKET

OCUL

OCUL

Ocular Therapeut
NASDAQ
9.20
+0.01
+0.11%
Opening 14:33 08/10 EDT
OPEN
9.20
PREV CLOSE
9.19
HIGH
9.31
LOW
9.04
VOLUME
758.74K
TURNOVER
--
52 WEEK HIGH
16.44
52 WEEK LOW
6.23
MARKET CAP
2.02B
P/E (TTM)
-6.5110
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at OCUL last week (0803-0807)?
Weekly Report · 10h ago
Bank of America Securities Sticks to Its Buy Rating for Ocular Therapeutix (OCUL)
TipRanks · 3d ago
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX), Ocular Therapeutix (OCUL) and Arcus Biosciences (RCUS)
TipRanks · 4d ago
Ocular Therapeutix: AXPAXLI Can Turn Retina Capacity Into A Commercial Moat
Seeking Alpha · 5d ago
Analysts Are Bullish on Top Healthcare Stocks: Ocular Therapeutix (OCUL), Keros Therapeutics (KROS)
TipRanks · 6d ago
Ocular Therapeutix Is Maintained at Buy by Chardan Capital
Dow Jones · 6d ago
Ocular Therapeutix Price Target Maintained With a $23.00/Share by Chardan Capital
Dow Jones · 6d ago
Ocular Therapeutix Faces Governance and Perception Risks from Insider Equity Compensation and Trading Practices
TipRanks · 6d ago
More
About OCUL
Ocular Therapeutix, Inc. is an integrated biopharmaceutical company. AXPAXLI, also known as OTX-TKI, the Company's investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX bioresorbable hydrogel-based formulation technology. Its pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA, a corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients, and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate PAXTRAVA, which is a travoprost intracameral hydrogel for the treatment of open-angle glaucoma or ocular hypertension. The ELUTYX technology provides delivery solutions for durable therapies for wet age-related macular degeneration (wet AMD), NPDR, DME, proliferative diabetic retinopathy, retinal vein occlusion, and other diseases.

Webull offers Ocular Therapeutix Inc stock information, including NASDAQ: OCUL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OCUL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading OCUL stock methods without spending real money on the virtual paper trading platform.